ReviewCancer immunology, immunotherapy : CII2025
Navigating TAM receptor dynamics in tumour immunotherapy.
Review in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Anticancer Effects of Cucurbitacin B and Meleagrin Associated with TYRO3 Downregulation in Colorectal Cancer Cells.International journal of molecular sciences · 2026Article
- Article
- Review
- Article
- Preclinical evaluation of CPL423: a novel potent small-molecule inhibitor of TAM family and FLT3 kinase for cancer therapy.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The TAM receptor family is getting more and more attention in the field of tumour immunity. Activation of TAM receptors not only aids in the survival and multiplication of tumour cells but also increases their likelihood of invading other cells and spreading. In addition, activation of TAM receptors helps to inhibit the anti-tumour immune response, allowing tumour cells to evade immune surveillance. In terms of therapeutic strategies, a number of inhibitors targeting TAM receptors are in preclinical and clinical development. Despite significant progress in clinical trials in recent years, challenges remain. This review delves into the kinetic characteristics of the TAM receptor family, their dual role in tumour immunity, and the transmission process of downstream signalling pathways. Based on this, we analysed and summarised the unique strategies and combination therapies for regulating tumour immunity using TAM receptor inhibitors. It not only helps to elucidate the key role of TAM receptors in tumour immunity but also provides new perspectives and strategies for future tumour therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.